FDA Warns GLP-1 Drugs Over Rare Vision Loss Risk

The US regulator, the Food and Drug Administration (FDA), is requiring safety label changes for GLP-1 receptor agonists after finding a potential increased risk of a rare eye condition that can …

Bayer gets FDA nod for first-in-class oral Factor XIa inhibitor Sunharbo, a potential blockbuster, for secondary stroke prevention.

The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.

The eye condition, which has been reported with all GLP-1 drugs, can cause significant vision loss.

FDA approves Bayer's Sunharbo (asundexian), the first factor XIa inhibitor, to prevent second strokes after a Phase 3 study showed a 26% risk cut.I made six edits in the story: …

There's a new alert on those popular GLP-1 weight loss drugs. The FDA is now mandating a warning label that the drugs may cause sudden blindness. ' Stephanie Gosk reports.

The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.

By Sneha S K and Michael Erman Nov 9 (Reuters) - The US Food and Drug Administration on Monday approved a new type of blood thinner developed by Bayer for the prevention of strokes in patients who …

Health regulators have found a consistent link between GLP-1 use and the eye condition NAION.

The FDA will now require makers of GLP-1s like Ozempic and Zepbound to add a warning about a rare condition causing vision loss to the drugs' labels.

The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic

You're going to want to keep an eye on this.

The agency is requiring GLP-1 manufacturers to warn the drugs can increase risk of 'eye stroke.

WASHINGTON (AP) — Popular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to p

The FDA is requiring manufacturers of GLP-1 receptor agonist therapies to include warnings regarding the risk for nonarteritic anterior ischemic optic neuropathy, according to a drug safety …

The FDA today informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.

The drugs could cause a condition that can lead to loss of vision.

The FDA is requiring new warnings about a rare eye condition linked to GLP-1 drugs used for weight loss and diabetes.

Compass Pathways, the London-based mental health biotech, said it has completed its New Drug Application to the US Food and Drug Administration (FDA) for COMP360, its investigational synthetic …

Nov 9 (Reuters) - The US health regulator on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for …

Adneuris Therapeutics, the pain-focused wholly-owned subsidiary of privately-held Tris Pharma, has submitted a New Drug Application to the US Food and Drug Administration (FDA) for cebranopadol for …

Federal regulators accuse Southern California-based pharmaceutical giant Amgen of distributing a misleading promotional video for Vectibix, a colorectal cancer treatment carrying potentially …

The Congressional Research Service (CRS) is continuing to point out the that Food and Drug Administration (FDA) still hasn't fulfilled a legal mandate to publish a list of known cannabinoids and …